Civmec – poised for a potential breakout above flag formation! (10 Sep 23)

Dear all With reference to my technical write-up on Boustead Singapore dated 23 Jun (click HERE), I pointed out that Boustead Singapore seems to be poised for a bullish breakout. It closed at $0.825 on 23 Jun and subsequently jumped 9% to touch an intraday high of $0.900 on 26 Jul. This compares favourably to STI which generated a 4.0% over the same period. Another stock, Civmec has recently caught my attention due to its chart development which may portend a potential bullish breakout. It closed $0.805 on 8 Sep. First of all, let’s understand what Civmec does.   Description […]

Lendlease Reit – Under-appreciated reit; yields >7% per annum! (3 Jul 23)

Dear all Lendlease Reit (“Lendlease”) caught my attention as according to consensus, it offers a potential dividend yield of around 7.1% in each of FY23F and FY24F (financial year ends in June). Furthermore, 7 analysts have rated Lendlease a buy with average analyst target price $0.85, representing a potential capital appreciation of around 28.8%. Lendlease closed at $0.660 on 30 Jun 2023. For a reit, such returns, if they indeed materialise, are rather substantial. As such, this leads me to dig deeper into the reit. Last month, I am fortunate to meet Mr Kelvin Chow, CEO of Lendlease Global Commercial […]

Sing Medical – Trades at a 13-month low price despite posting record 1HFY21 results (3 Feb 22)

Dear all On 29 Dec 2020, I have published a write-up on Sing Medical (“SMG”) where I outlined that the risk reward on SMG seems favourable at $0.315, given a potential share transaction scenario (click HERE). Since 29 Dec, SMG rose approximately 32% to trade $0.415 – 0.420 on several occasions in Feb 2021. Subsequently, it dropped sharply in Apr 2021 when it announced that the potential share transaction has lapsed. Fast forward to 31 Jan 2022 and SMG closed at a 13-month low at $0.290. This is notwithstanding its sterling record 1HFY21 results announced in Aug last year where […]